Titre:
  • A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: The GAMMA trial
Auteur:Fuchs, Charles C.S.; Bodoky, G.; Ikeda, Masafumi; Melichar, Bohuslav; Nemecek, Shinichi; Ohkawa, Anna; Swieboda-Sadlej, Sergei; Tjulandin, Eric; Van Cutsem, Robert; Loberg, Vincent; Haddad, Sergio; Azevedo, Jennifer J.L.; Gansert, Bruce B.A.; Bach, Alfredo; Carrato, Takuji; Okusaka, Jean-Luc; Van Laethem, Lara L.R.; Lipton, Hanno; Riess, Cezary; Szczylik, Malcolm J; Moore, Michel; Peeters,
Informations sur la publication:Annals of oncology, 26, 5, page (921-927), mdv027
Statut de publication:Publié, 2015-05
Sujet CREF:Hématologie
Cancérologie
Mots-clés:Biomarker
Ganitumab
Gemcitabine
IGF-1 receptor
Pancreatic cancer
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdv027
info:scp/84929083437